. 2023 Mar 7;4(3):100972. doi: 10.1016/j.xcrm.2023.100972

Table 1.

Inclusion and exclusion criteria of enrolled patients

Inclusion criteria	Exclusion criteria
(1) Subjects with age ≥ 18 years and ECOG score of 0–1 (2) subjects with pancreatic cancer confirmed by histology or cytology (3) The patients with potentially resectable pancreatic cancer were imaged 4) The subjects should meet the following hematological indexes: neutrophil count ≥ 1.5 * 10ˆ9/L, hemoglobin ≥ 10 g/dL, platelet count ≥ 100 * 10ˆ9/L (5) The subjects should meet the following biochemical indicators: total bilirubin ≤ 1.5* ULN; AST and ALT < 1.5* ULN; creatinine clearance rate ≥ 60 mL/min (6) Subjects of childbearing age need to take appropriate protective measures (contraceptive measures or other methods of birth control) before entering the group and during the test (7) Subjects who have signed informed consent (8) Subjects who were able to follow the protocol and follow-up procedures	(1) patients who have received systematic antitumor treatment (2) patients with previous history of other tumors, except for cervical cancer in situ, treated squamous cell carcinoma or bladder epithelial tumor (TA and TIS), or other malignant tumors that have received radical treatment (at least 5 years before enrollment) (3) patients with active bacterial or fungal infection (≥ level 2 of NCI-CTC, 3rd Edition) (4) patients with HIV, HCV, or HBV infection, uncontrollable coronary artery disease or asthma, uncontrollable cerebrovascular disease, or other diseases considered by researchers to be out of the group (5) patients with autoimmune diseases or immune defects who are treated with immunosuppressive drugs (6) pregnant and lactating women; pregnant women of childbearing age must test negative within 7 days before entering the group (7) patients with drug abuse or clinical or psychological or social factors that make informed consent or research implementation affected (8) patients who may be allergic to PD-1 monoclonal antibody immunotherapy drugs

Inclusion criteria

Exclusion criteria

(1)
Subjects with age ≥ 18 years and ECOG score of 0–1
(2)
subjects with pancreatic cancer confirmed by histology or cytology
(3)
The patients with potentially resectable pancreatic cancer were imaged
4)
The subjects should meet the following hematological indexes: neutrophil count ≥ 1.5 * 10ˆ9/L, hemoglobin ≥ 10 g/dL, platelet count ≥ 100 * 10ˆ9/L
(5)
The subjects should meet the following biochemical indicators: total bilirubin ≤ 1.5* ULN; AST and ALT < 1.5* ULN; creatinine clearance rate ≥ 60 mL/min
(6)
Subjects of childbearing age need to take appropriate protective measures (contraceptive measures or other methods of birth control) before entering the group and during the test
(7)
Subjects who have signed informed consent
(8)
Subjects who were able to follow the protocol and follow-up procedures

(1)
patients who have received systematic antitumor treatment
(2)
patients with previous history of other tumors, except for cervical cancer in situ, treated squamous cell carcinoma or bladder epithelial tumor (TA and TIS), or other malignant tumors that have received radical treatment (at least 5 years before enrollment)
(3)
patients with active bacterial or fungal infection (≥ level 2 of NCI-CTC, 3rd Edition)
(4)
patients with HIV, HCV, or HBV infection, uncontrollable coronary artery disease or asthma, uncontrollable cerebrovascular disease, or other diseases considered by researchers to be out of the group
(5)
patients with autoimmune diseases or immune defects who are treated with immunosuppressive drugs
(6)
pregnant and lactating women; pregnant women of childbearing age must test negative within 7 days before entering the group
(7)
patients with drug abuse or clinical or psychological or social factors that make informed consent or research implementation affected
(8)
patients who may be allergic to PD-1 monoclonal antibody immunotherapy drugs